The deals cover development and commercialization of next-generation sequencing and digital PCR assays for minimal residual disease detection.

Northwestern Medical will begin using PathAI's AISight digital pathology image management system as part of the deal.

Last week, readers were most interested in a story about what's up Roche's sleeve as it talked about its plans during its investor day.

The BLIPI test device was used to monitor babies' immune status from a drop of whole blood and detected sepsis within 15 minutes, enabling incubator-side testing.

Of the 30 companies included in the list, 15 saw their stock prices decline, while 15 saw their share prices rise.

The RiskReveal assay was used to determine which early-stage non-squamous NSCLC patients should undergo adjuvant chemotherapy.

Investors and consultants in the space said that they have seen rising enthusiasm among investors as recent funding rounds ...

NEW YORK — Genedrive said Friday that it has received CE marking under the EU's In Vitro Diagnostic Medical Device Regulation (IVDR) for its point-of-care CYP2C19 ID Kit genotyping platform, which is ...

The firm touted new assays, provided an update on its nanopore sequencer, and offered insights into upcoming pipeline ...

NEW YORK – Researchers from Johns Hopkins University's Sidney Kimmel Comprehensive Cancer Center reported last week that they have developed a plasma-based fragmentomic test that could help to ...

NEW YORK – In May, the US Food and Drug Administration (FDA) issued the first 510(k) clearance of a blood-based test for Alzheimer's disease, a development that is likely to drive broader ...